Unmet Need
INDICATION & LIMITATION OF USE

DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

With so many PrEP candidates at risk, why aren’t more being prescribed a PrEP medication?

Click the speaker icon to unmute or mute the video.

Play video icon

Click the speaker icon to unmute or mute the video.

Uptake of PrEP use in the United States remains low despite significant HIV risk1

Nearly

1 million males were indicated for a PrEP medication by 2018

However, only 21% of these patients were prescribed a PrEP medication2

Of new HIV diagnoses in 2018,3

39%

WERE BLACK MSM

and

31%

WERELATINO MSM

Yet, in a CDC study of PrEP use among MSM at risk (n=4056), only4

6%

WERE BLACK MSM

and

8%

WERELATINO MSM

Help meet HIV risk head-on—talk to your appropriate patients about DESCOVY FOR PrEP®.

CDC=Centers for Disease Control and Prevention; MSM=men who have sex with men.